Clinical comments on genetic marker prevalence (factor V Leiden, prothrombin 20210A and homozygous methylenetetrahydrofolate reductase form [Ho-MTHFR]): Based on a study conducted in Health Department no. 19 of the Valencian Community;Prevalencia de factor V Leiden, protrombina 20210 a y homozigosis de la MTHFR: A propósito de un estudio en el Departamento de Salud no. 19 de la Comunidad Valenciana

Revista Clinica Espanola

Volumn 207, Issue 1, 2007, Pages 26-28

  Garcia Hernandez M C ^a   Romero Casanova, A ^a,b   Marco Vera, P ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b UNIVERSITY OF ALICANTE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

GENETIC MARKER; HUMAN; PREVALENCE; PUBLIC HEALTH SERVICE; RELATIVE; REVIEW; STATISTICAL SIGNIFICANCE;

EID: 33847033335     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13098497     Document Type: Article

References (20)

1. British Commite for Standars in Haematology.Guideliness on the investigation and management of thrombophilia. J Clin Pathol. 1990;43:703-9.
2. Bertina RM, Reistma PM, Rosendal FR, Van der Brouke JP. Resistance to activated protein C and factor V Leiden as a risk factor for venous thrombosis. Thromb Haemost. 1995;74:449-53.
3. Dahlback B. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation and clinical management. Semin Hematol. 1997;14:403-11.
4. Koster T, Rosendaal FR, Briet E, Van der Meer FJ, Colly LP, Trienekens PH. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995;85:2756-61.
5. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-8.
6. Ridker PM, Miletich JP, Stampfer MF, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800-2.
7. Lozano F, Alberca I, Balanzategui A, Almazán A, Gómez-Alonso A. Nuevas trombofilias (RPCa y FII20210). Análisis de 167 pacientes. Cir Esp. 1998;64:361.
8. Rosendaal FR, Doggen CJM, Zivelin A, Arruda VR, Aiach M. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998;79:706-8.
9. McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis. 1957;22:215-27.
10. Gonzalez I, Souto JC, Mateo J, Córdoba A, Blanco-Vaca F, Fontcuberta J. Moderate hyper-homocysteinemia is highly prevalent defect in Spanishpatients with venous thromboembolic disease. Haematologica. 1998;83:1126-7.
11. Mc Cully KS. Homocysteine and vascular disease. Nat Med. 1996;2:386-9.
12. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med. 1998;158:2101-6.
13. Den Heiher V, Rosendaal FR, Blom HJ, Gerrits WBJ, Bos GMJ. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost. 1998;80:874-7.
14. Keijzer MB, den Heijer M, Blom HJ, Bos GM, Willems HP, Gerrits H, et al. Interaction between hyperhomociysteinemia, mutated methylentetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost. 2002;88(5):723-8.
15. Zalavras ChG, Giotopoulou S, Dokou E, Mitsis M, Ioannou HV, Tzolou A, et al. Lack of assciation between the C677T mutation in the 5,10- methylentetrahydrofolate reductase gene and venous thromboembolism in Northwestern Greece. Int Angiol. 2002;21(3):268-71.
16. De Stefano V, Casorelli I, Rossi E, Zappacosta B, Leone G. Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism. Sem Thromb Haemost. 2000;26:305-11.
17. Margaglione M, D'Andrea G, Coliazzo D, Cappucci G, Del Popolo A, Brancaccio V, et al. Coexistence of factor V Leiden and factor 11 20210A and recurrent venous thromboembolism. Thromb Haemost. 1999;82:1583-7.
18. Couturaud F, Oger E, Abalain JH, Chenu E, Guias B, Floch HH. Methylen-tetrahydro-folate reductase C677T genotype and venous thromboembolic disease. Respiration. 2000;67(6):657-61.
19. Den Heijer M, Bloom HJ, Gerrits WBJ, Rosendaal FR, Haak HL. Is Hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet. 1995;345: 882-5.
20. Ray JG. Meta-analysis of hyperhomocysteinemia aa a risk factor for venous thromboembolic disease. Arch Intern Med. 1998;158:2101-6.